Sertraline in stroke‐associated lability of mood

@article{Burns1999SertralineIS,
  title={Sertraline in stroke‐associated lability of mood},
  author={Alistair Burns and Eve Russell and Hilary Stratton-Powell and Pippa Tyrell and Paul O'Neill and Robert Baldwin},
  journal={International Journal of Geriatric Psychiatry},
  year={1999},
  volume={14}
}
To assess whether a selective serotonin reuptake inhibitor is effective in the treatment of stroke‐associated lability of mood. 

Associations of serotonergic genes with poststroke emotional incontinence

TLDR
Polymorphisms of serotonin transporter and serotonin 2a receptor genes may regulate serotonergic signaling at brain synapses, and associations with PSEI in an East Asian population are investigated.

The antidepressant sertraline: A review of its uses in a range of psychiatric and medical conditions

Although sertraline was initially introduced as an antidepressant, it can be prescribed for a wide range of psychiatric and medical conditions. We review the pharmacology, the adverse effects, the

Selective Serotonin Reuptake Inhibitors for Stroke Recovery.

TLDR
A meta-analysis of all (published and unpublished) randomized controlled trials of SSRI compared with control, given within the first year of stroke, to determine the effect on dependency, disability, and other important clinical outcomes.

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.

TLDR
If SSRIs are more effective than placebo or usual care at improving outcomes in people less than 12 months post-stroke, and to determine whether treatment withSSRIs is associated with adverse effects, are determined.

The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.

TLDR
Sertraline's efficacy for both mood and anxiety disorders, relatively weak effect on the cytochrome P450 system, and tolerability profile and safety in overdose are factors that contribute to make it a first-line agent for treatment in both primary and tertiary care settings.

Selective Serotonin Reuptake Inhibitors for Stroke Recovery: A Systematic Review and Meta-analysis

TLDR
A meta-analysis of all (published and unpublished) randomized controlled trials of SSRI compared with control, given within the first year of stroke, to determine the effect on dependency, disability, and other important clinical outcomes.

Behavioral Symptoms in Vascular Cognitive Impairment and Vascular Dementia

  • J. O'Brien
  • Psychology, Medicine
    International Psychogeriatrics
  • 2003
Noncognitive or behavioral and psychological symptoms (BPSD) are common in vascular dementia. Many occur with the same frequency as in Alzheimer's disease, though depression, emotional lability, and

Selective serotonine reuptake inhibitors prevents emotional lability in healthy subjects.

TLDR
The antidepressant drugs of the family of selective serotonine reuptake inhibitors (SSRI) improve EL within a few days in both depressive and neurological disorders.

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.

TLDR
WhetherSSRIs improve recovery after stroke, and whether treatment with SSRIs was associated with adverse effects, was determined, and there were statistically significant benefits of SSRI on both of the primary outcomes.

Dextromethorphan Plus Ultra Low‐Dose Quinidine Reduces Pseudobulbar Affect

To evaluate dextromethorphan combined with ultra low‐dose quinidine (DMq) for treating pseudobulbar affect (PBA) in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).
...

References

SHOWING 1-10 OF 21 REFERENCES

Reliability of Scandinavian Neurological Stroke Scale

The Scandinavian hemodilution study in acute ischemic stroke used the neurological scale presented here in assessing prognosis and long-term outcome. The purpose of the present study was to test its i

The Use of Imipramine (“Tofranil”) and Other Psychotropic Drugs in Organic Emotionalism

TLDR
A “double-blind” form of therapeutic trial was engaged, comparing two dose strengths of imipramine with phenobarbitone and dummy tablets given in random sequence to each patient, confirming the favourable impression of imIPramine being confirmed and attempting to assess the effect on this symptom of two other drugs of related pharmacology.

Fluoxetine as a treatment for emotional lability after brain injury.

TLDR
An open trial using fluoxetine, a newer antidepressant with a specific serotonergic action, in the treatment of emotional lability due to brain injury and the drug was well tolerated with no reported side-effects.

Treatment of pathologic laughing and weeping with amitriptyline.

TLDR
It is concluded that amitriptyline is effective in the treatment of this disturbance of affective expression, and that this effect is distinct from the antidepressant effect of the medication.

Mood Disorders in the Year after First Stroke

TLDR
While there was a high cumulative incidence of psychiatric disorder, little of it persisted: only two cases of major depression were present for the whole 12 months and undue emphasis has been placed on major depression as a specific syndrome following stroke.

Does post‐traumatic stress disorder occur after stroke: a preliminary study

TLDR
Whether psychological symptoms consistent with post‐traumatic stress disorder (PTSD) could occur after stroke as a consequence of the sudden and unpredictable occurrence of a life‐threatening internal stressor is examined.

Emotionalism after stroke.

TLDR
Emotionalism is common after stroke and is associated with symptoms of a more general mood disturbance and is found especially in patients with left frontal and temporal lesions.

Affective Disorders and Cerebral Vascular Disease

TLDR
Post-stroke mania is strongly associated with both a right hemisphere lesion in a limbic-connected area and a second predisposing factor, such as genetic loading for affective disorder, pre-existing subcortical atrophy or seizure disorder, which may be mediated through frontal lobe dysfunction.

A New Depression Scale Designed to be Sensitive to Change

TLDR
The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described, and its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.